Form 4: Rafael Holdings CEO Acquires Shares and Options in Merger with Cyclo Therapeutics
SEC Form 4 Filing
William Conkling, CEO of Rafael Holdings, acquired shares and options through a business combination with Cyclo Therapeutics.
Summary
- William Conkling, CEO of Rafael Holdings, acquired 27,454 shares of Class B Common Stock on March 25, 2025, as part of a merger with Cyclo Therapeutics.
- These shares were received in exchange for 77,884 shares of Cyclo Therapeutics common stock, based on an exchange ratio of 0.3525.
- Following the transaction, Conkling beneficially owns 564,455 shares of Rafael Holdings stock.
- Conkling also acquired options to purchase 2,362 and 5,485 shares of Class B Common Stock, with exercise prices of $3.89 and $3.63, respectively.
- These options were also received in exchange for employee stock options previously granted to Conkling by Cyclo Therapeutics.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine filing related to a merger. The CEO's increased stake could be seen as a positive signal, but it's not overwhelmingly bullish.
Positives
- The CEO's increased stake in Rafael Holdings could signal confidence in the company's future prospects following the merger.
Industry Context
Mergers and acquisitions are common in the pharmaceutical and biotechnology industries as companies seek to expand their product pipelines, technologies, or market share. Insider transactions related to these events are closely watched by investors.
Comparison to Industry Standards
- It's common for executives to receive stock options and restricted stock as part of their compensation packages, especially in growth-oriented companies.
- The vesting schedules for the restricted stock are fairly standard, with quarterly and annual vesting dates.
- The exchange ratio in the merger appears to be based on a valuation of Cyclo Therapeutics relative to Rafael Holdings at the time of the agreement.
Stakeholder Impact
- Shareholders may view the CEO's increased ownership as a positive sign.
- Employees of both Rafael Holdings and Cyclo Therapeutics may be affected by the integration of the two companies.
Key Dates
| Date | Description |
|---|---|
| 06/03/2024 | Date of original grant of employee stock option to Mr. Conkling to purchase 15,562 shares of Cyclo common stock at an exercise price of $1.28. |
| 06/06/2023 | Date of original grant of employee stock option to Mr. Conkling to purchase 6,700 shares of Cyclo common stock at an exercise price of $1.37. |
| 03/25/2025 | Date of transaction: Acquisition of shares and options due to merger. |
| 03/25/2025 | Date options became exercisable. |
| 04/24/2025 | Date of Form 4 filing. |
| 06/21/2025 | First quarterly vesting date for 38,983 restricted shares. |
| 09/21/2025 | Second quarterly vesting date for 38,983 restricted shares. |
| 10/25/2025 | Vesting date for 10,000 restricted shares. |
| 12/21/2025 | Vesting date for 38,986 restricted shares. |
| 01/13/2026 | Vesting date for 15,000 restricted shares. |
| 10/25/2026 | Vesting date for 10,000 restricted shares. |
| 01/13/2027 | Vesting date for 15,000 restricted shares. |
| 10/25/2027 | Vesting date for 10,000 restricted shares. |
| 01/13/2028 | Vesting date for 15,000 restricted shares. |
| 01/13/2029 | Vesting date for 15,000 restricted shares. |
| 06/03/2034 | Expiration date for option to purchase 5,485 shares. |
| 06/06/2033 | Expiration date for option to purchase 2,362 shares. |
Keywords
Rafael Holdings, William Conkling, Cyclo Therapeutics, Merger, Class B Common Stock, Stock Options, Beneficial Ownership, Form 4, SEC
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.